STOCK TITAN
  1. Home
  2. News
  3. PTCT

PTC Therapeutics Inc - PTCT STOCK NEWS

Welcome to our dedicated news page for PTC Therapeutics (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on PTC Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PTC Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PTC Therapeutics's position in the market.

News
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) reported unaudited 2023 total revenue of $946 million, showing 35% year-over-year growth. Regulatory filings for sepiapterin in PKU remain on track for 2024, with multiple study readouts planned for 2024, including 12-month interim data from the PIVOT-HD study of PTC518 in HD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.49%
Tags
none
-
News
PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024. The presentation will be webcast live on the company's website and archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
conferences
-
News
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) approved non-statutory stock options and restricted stock units for two new employees on Dec. 10, 2023. The stock options have an exercise price of $26.39 per share, with a 10-year term and vesting over four years. The RSUs will also vest over four years, with 25% of the original shares vesting on each annual anniversary of the employee's new hire date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
News
PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) provides an update on the regulatory activities for Translarna™ (ataluren) in Europe and the United States. The company has submitted a briefing document for the re-examination of the initial CHMP negative opinion on the renewal of conditional marketing authorization of Translarna in Europe. In the U.S., PTC participated in a Type C meeting with the FDA to discuss a potential path to resubmitting a New Drug Application for Translarna. The company expects a follow-up meeting with the FDA in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
none
-
News
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
PTC Therapeutics, Inc. approved non-statutory stock options and restricted stock units (RSUs) for 21 new employees. The stock options have an exercise price of $18.45 per share and a 10-year term, vesting over four years. The RSUs vest over four years as well. The grants were made as an inducement for the new hires' employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
Rhea-AI Summary
PTC Therapeutics announces Q3 2023 financial results and corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.71%
Tags
earnings
News
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
Rhea-AI Summary
PTC Therapeutics agrees to monetize up to $1.5 billion of the Evrysdi royalty stream with Royalty Pharma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.98%
Tags
none
-
News
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results
Rhea-AI Summary
PTC Therapeutics to host webcast conference call to report Q3 2023 financial results and provide business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
conferences earnings
-
News
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
Rhea-AI Summary
PTC Therapeutics announces strategic prioritization and workforce reduction, plans to submit re-examination request for Translarna CHMP opinion
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
none
News
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
Rhea-AI Summary
PTC Therapeutics receives negative opinion from CHMP on Translarna, plans to request re-examination
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.77%
Tags
none
Stock PTCT logo
PTC Therapeutics Inc

Nasdaq:PTCT

PTCT Rankings

#1811 Ranked by Market Cap
#4692 Ranked by Stock Gains
N/A Ranked by Dividends

PTCT Stock Data

2.02B
56.48M
2.79%
112.93%
13.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South Plainfield

About PTCT

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.